Dianthus Therapeutics (DNTH) Restructuring Costs (2023)
Dianthus Therapeutics (DNTH) posted quarterly Restructuring Costs of $1.9 million for Q2 2023, down 89.35% quarter-over-quarter from $18.0 million in Q1 2023.
Powered by 
Analysis
Dianthus Therapeutics (DNTH) Restructuring Costs (2023) Analysis & Trends
Dianthus Therapeutics' Restructuring Costs history runs 1 years deep, the most recent figure standing at $1.9 million for Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.72 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.56 Bn | 58.38 Bn | 1.37 Bn |
| 4 | Moderna | 57.87 Bn | 52.73 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - |
| 6 | BeOne Medicines | 40.08 Bn | 34.98 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.20 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.54 Bn | 27.70 Bn | - |
| 9 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn |
| 10 | Dianthus Therapeutics | 4.07 Bn | 3.66 Bn | - |